COVID-19 and IBD drugs: should we change anything at the moment?
- PMID: 33214164
- DOI: 10.1136/gutjnl-2020-323247
COVID-19 and IBD drugs: should we change anything at the moment?
Keywords: azathioprine; covid-19; crohn's disease; inflammatory bowel disease; infliximab.
Conflict of interest statement
Competing interests: CWL has received research support from Abbvie and Gilead, acted as a consultant to Abbvie, Janssen, Takeda, Pfizer, MSD, Hospira, Pharmacosmos, GSK, Gilead, Topivert, Vifor Pharma, Dr Falk, Oshi Health, Trellus Health and Iterative Scopes; he has received speaking fees and travel support from Pfizer, Janssen, Abbvie, MSD, Takeda, Shire, Ferring, Hospira, Warner-Chilcott and Dr Falk. PMI has received fees for speaking on the behalf of or acting in an advisory capacity for AbbVie, Arena, Biogen, Celgene, Ferring, Prometheus, Shire, Warner Chilcott, Takeda, MSD, Vifor Pharma, Pharmacosmos, Topivert, Genentech, Hospira, Samsung Bioepis, VH2, Janssen, Sandoz, Lilly and Roche and has received financial support for research from MSD, Pfizer and Takeda. LB has received consulting fees from Janssen and Pfizer, lecture fees from Abbvie, Janssen, MSD, Ferring Pharmaceuticals, Mayoly-Spendler, Takeda and Tillots, and research support from Abbott, Ferring Pharmaceuticals, Hospira-Pfizer, Janssen, MSD, Takeda and Tillots.
Comment on
-
Effect of IBD medications on COVID-19 outcomes: results from an international registry.Gut. 2021 Apr;70(4):725-732. doi: 10.1136/gutjnl-2020-322539. Epub 2020 Oct 20. Gut. 2021. PMID: 33082265 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical